Allena Fundamentals

Allena Pharmaceuticals fundamentals help investors to digest information that contributes to Allena Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Allena Stock. The fundamental analysis module provides a way to measure Allena Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Allena Pharmaceuticals stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
Allena Pharmaceuticals Interest Expense is projected to increase significantly based on the last few years of reporting. The past year's Interest Expense was at 976,000. The current year Weighted Average Shares is expected to grow to about 73.3 M, whereas Consolidated Income is forecasted to decline to (52.5 M).

Allena Shares Owned by Institutions Analysis

Allena Pharmaceuticals' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Shares Held by Institutions 
Funds and Banks 
More About Shares Owned by Institutions | All Equity Analysis

Current Allena Pharmaceuticals Shares Owned by Institutions

  7.42 %  
Most of Allena Pharmaceuticals' fundamental indicators, such as Shares Owned by Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Allena Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Compare to competition

Based on the latest financial disclosure, 7.42% of Allena Pharmaceuticals are shares owned by institutions. This is 83.38% lower than that of the Biotechnology sector and 84.38% lower than that of the Health Care industry. The shares owned by institutions for all United States stocks is 81.08% higher than that of the company.

Allena Pharmaceuticals Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Allena Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Allena Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Allena Pharmaceuticals competition to find correlations between indicators driving Allena Pharmaceuticals's intrinsic value. More Info.
Allena Pharmaceuticals is rated second in debt to equity category among related companies. It is rated fourth in return on asset category among related companies . The current year Average Assets is expected to grow to about 42.4 M. The current year Tangible Asset Value is expected to grow to about 41.7 M. Comparative valuation analysis is a catch-all model that can be used if you cannot value Allena Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Allena Pharmaceuticals' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Allena Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Allena EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Allena Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Allena Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Allena Pharmaceuticals by comparing valuation metrics of similar companies.
Allena Pharmaceuticals is currently under evaluation in ebitda category among related companies.

Allena Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Allena Pharmaceuticals from analyzing Allena Pharmaceuticals' financial statements. These drivers represent accounts that assess Allena Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Allena Pharmaceuticals' important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(585.13 K)(727.51 K)(1.39 M)(798.91 K)(2.32 M)(2.5 M)
Average Assets72.86 M76.56 M46.32 M30.92 M37.35 M42.38 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(21.13 M)(36.15 M)(47.45 M)(32.17 M)(47.32 M)(51.06 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(21.13 M)(36.15 M)(46.96 M)(31.57 M)(46.95 M)(50.66 M)
Earnings before Tax(21.65 M)(35.65 M)(47.34 M)(32.84 M)(48.66 M)(52.5 M)
Average Equity11.8 M62.67 M29.69 M17.44 M20.17 M19.75 M
Free Cash Flow(21.12 M)(32.16 M)(43.75 M)(28.79 M)(46.34 M)(50 M)
Invested Capital3.6 M7.8 M3.69 M8.3 M(531 K)(544.97 K)
Invested Capital Average17.08 M6.62 M5.6 M6.26 M4.99 M6.62 M
Tangible Asset Value96.25 M65.23 M34.11 M38.93 M34.76 M41.68 M
Working Capital88.49 M58.71 M22.13 M31.13 M17.33 M17.78 M

Allena Fundamentals

About Allena Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Allena Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Allena Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Allena Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. Allena Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NMS Exchange. It employs 17 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Allena Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Forecasting Now


Equity Forecasting

Use basic forecasting models to generate price predictions and determine price momentum
All  Next Launch Module

Pair Trading with Allena Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allena Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allena Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Allena Pharmaceuticals

+0.76BEAMBeam TherapeuticsInc Normal TradingPairCorr

Moving against Allena Pharmaceuticals

-0.63JNJJohnson Johnson TrendingPairCorr
-0.59JPMJPMorgan Chase Fiscal Year End 13th of January 2023 PairCorr
-0.56WMTWalmart TrendingPairCorr
-0.55MRNAModerna Potential GrowthPairCorr
The ability to find closely correlated positions to Allena Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allena Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allena Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allena Pharmaceuticals to buy it.
The correlation of Allena Pharmaceuticals is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allena Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allena Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allena Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Trending Equities. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for analysis

When running Allena Pharmaceuticals price analysis, check to measure Allena Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allena Pharmaceuticals is operating at the current time. Most of Allena Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Allena Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Allena Pharmaceuticals' price. Additionally, you may evaluate how the addition of Allena Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bond Directory
Find actively traded corporate debentures issued by US companies
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Transaction History
View history of all your transactions and understand their impact on performance
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Is Allena Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allena Pharmaceuticals. If investors know Allena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allena Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Allena Pharmaceuticals is measured differently than its book value, which is the value of Allena that is recorded on the company's balance sheet. Investors also form their own opinion of Allena Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Allena Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allena Pharmaceuticals' market value can be influenced by many factors that don't directly affect Allena Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allena Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Allena Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allena Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.